Finally, altered PTEN expression is associated with poor prognosis in lung cancer [12,25], frequently characterized by aberrant AKT activation due to loss of PTEN or PIK3CA/AKT1 activating mutations, often leading to treatment resistance [26]. This evidence concerns the gene AKT1 and lung cancer.